Skip to content

EFECAB: Improving Pig Management to Prevent Epilepsy in Burkina Faso

EFECAB: Improving Pig Management to Prevent Epilepsy in Burkina Faso

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03095339
Acronym
EFECAB
Enrollment
58
Registered
2017-03-29
Start date
2011-02-21
Completion date
2015-01-31
Last updated
2018-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cysticercosis

Keywords

Burkina Faso, Community-based randomized controlled trial, Cysticercosis, Implementation Research, Effectiveness

Brief summary

This is a pre-post randomized community-based controlled trial aimed at estimating the effectiveness of an educational package developed using PRECEDE PROCEED to reduce the cumulative incidence of Taenia solium cysticercosis in three Provinces of Burkina Faso. The study design included an 18-months baseline study to measure baseline cumulative incidence of cysticercosis followed by an 18-month post randomization study to measure the effectiveness of the intervention. Sixty villages of three Provinces of Burkina Faso were included. The primary outcome was the change in the baseline to post randomization cumulative incidence in the intervention group compared to the control group.

Interventions

The educational package was offered to 30 villages post randomization. The field team completed the SARAR PHAST with community members for 2-3 days in each intervention village. The movie was projected every night for 2-3 days in each intervention village.

Sponsors

AFRICSanté
CollaboratorOTHER
Institute of Tropical Medicine, Belgium
CollaboratorOTHER
Institut de Recherche en Sciences de la Sante, Burkina Faso
CollaboratorOTHER_GOV
University of Ouagadougou, Burkina Faso
CollaboratorOTHER
University Hospital, Limoges
CollaboratorOTHER
Centre Universitaire Souro Sanou
CollaboratorUNKNOWN
Technical University of Munich
CollaboratorOTHER
Brown University
CollaboratorOTHER
University of Oklahoma
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

This is a pre-post community-based randomized controlled trial. The unit of randomization is the village (community)

Eligibility

Sex/Gender
ALL
Age
5 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

The unit of randomization and analysis of this study is the village. Therefore, the eligibility criteria were determined at the village level. Inclusion Criteria: * Population of at least 1000 at the 2006 census * Present on the map of the Institut Géographique du Burkina 2000 * Separated from another village by at least 5 kilometers.

Exclusion criteria

* Village located on a National or Provincial road * Village located within 20 km of Koudougou or Ouagadougou * Regional or Provincial Capital * Absence of pigs in the village At the individual level, the following eligibility criteria were used: Inclusion Criteria: * Aged 5 years old or more * Has lived in the village for at least 12 months * Not planning to move in the next three years

Design outcomes

Primary

MeasureTime frameDescription
Human active cysticercosis cumulative incidencebaseline, 18 months follow-up pre randomization, 18 months follow-up post randomizationSero conversion to the AgELISA test to detect antigens of cysticercosis

Secondary

MeasureTime frameDescription
Porcine active cysticercosis prevalencebaseline, 18 months follow-up pre randomization, 18 months follow-up post randomizationSero-positivity to the AgELISA test to detect antigens of cysticercosis
Change in knowledge, attitude and practicesbaseline, 18 months follow-up pre randomization, 18 months follow-up post randomizationChange in answers to the questionnaire through time
Cumulative incidence of epilepsy and progressively worsening severe chronic headachesbaseline, 18 months follow-up pre randomization, 18 months follow-up post randomizationdevelopment of neurological disorders among those followed up at least twice
Stigmatization of epilepsy18 months follow-up post randomizationAttitudes and knowledge regarding epilepsy post randomization

Countries

Burkina Faso

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026